Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload

REFERENCES 1. Wang SA, Hasserjian RP. Erythroid proliferations in myeloid neoplasms. Hum Pathol 2012;43:153-64. 2. Liu W, Hasserjian RP, Hu Y, et al. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. Mod Pathol 2011;24:375-83. 3. Liu CJ, Hong YC, Yang CF, et al. Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification. Leuk Lymphoma 2012;53:289-94. 4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51. 5. Guo C, Inghirami G, Ibrahim S, Sen F. Epistaxis and severe weakness in a patient with multiple myeloma. Therapy-related acute myeloid leukemia, pure erythroid leukemia. Arch Pathol Lab Med 2006;130:1075-6. 6. Funakoshi Y, Matsuoka H, Yamamoto K, et al. Therapy-related pure erythroid leukemia with hepatic infiltration and hemophagocytic syndrome. Intern Med 2011;50:3031-5. 7. Xu M, Finn LS, Tsuchiya KD, Thomson B, Pollard J, Rutledge J. Pure erythroid leukemia following precursor B-cell lymphoblastic leukemia. Pediatr Dev Pathol 2012;15:76-8. 8. Sadrzadeh H, Hasserjian R, Fathi AT. Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia. Am J Hematol 2013;88:240-1. 9. Pagano L, Pulsoni A, Mele L, et al. Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group. Ann Oncol 2001;12:203-7. 10. Ayala RM, Martinez-Lopez J, Albizua E, Diez A, Gilsanz F. Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol 2009;84: 79-86.